The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
Sign in to access this content
Sign InORIC Pharmaceuticals has announced the selection of 400 mg once daily as the Recommended Phase 3 Dose (RP3D) for its drug Rinzimetostat. The drug will be utilized in combination with darolutamide for the upcoming Himalayas-1 global Phase 3 registrational trial. This study specifically targets patients with post-abiraterone metastatic castration-resistant prostate cancer (mCRPC). The clinical trial initiation is currently projected for the first half of 2026, following positive dose optimization data that supports its potential as a best-in-disease treatment. This selection marks a significant clinical milestone for the biotech company, signaling steady progress toward potential commercialization. Investors view this development as a positive step in ORIC's oncology pipeline, despite the trial start being scheduled for 2026.